Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DeteCTCs

Financiado

Cerrado

The first multi cancer liquid biopsy test for detection of early stage cancer an...

The first multi cancer liquid biopsy test for detection of early stage cancer and minimal residual disease from a blood draw With over 10M deaths and an annual cost of €199B, cancer poses an immense burden on individuals, healthcare, and society. To reduce cancer deaths, improve patients’ quality of life, and lower the economic cost, both early detectio... ver más

30/06/2024

ICELLATE MEDICAL A...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

ICELLATE MEDICAL AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-06-30

EIC-FTI-2018-2020: Fast Track to Innovation (FTI)

I+D

Cerrada hace 6 años

0% 79% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

ICELLATE MEDICAL AB

1.02M€ | Lider

RJOGLASS SOLAR, SA

566.93K€ | Participante

CAU

5.00K€ | Participante

QIAGEN AARHUS

518.44K€ | Participante

Proyectos interesantes

GUIDE.MRD

Medical Technol...

Data Science

34M€ Cerrado

FG_WIT

Medical Technol...

Data Science

75K€ Cerrado

PID2020-120306RB-I00

Medical Technol...

Data Science

184K€ Cerrado

MAINTRAC-Auto

Medical Technol...

Data Science

71K€ Cerrado

CTCapture_2.0

Medical Technol...

Data Science

150K€ Cerrado

NO-META

Medical Technol...

Data Science

71K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 36 meses Fecha Inicio: 2021-06-01
Fecha Fin: 2024-06-30

Líder del proyecto

ICELLATE MEDICAL AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto With over 10M deaths and an annual cost of €199B, cancer poses an immense burden on individuals, healthcare, and society. To reduce cancer deaths, improve patients’ quality of life, and lower the economic cost, both early detection and treatment are key. Current methods for early cancer screening and minimal residual disease (MRD) testing include inconvenient and costly procedures such as mammograms, Pap smears, colonoscopies. Unfortunately, for the majority of cancers, no early detection method exists. Blood-based tests offer an attractive opportunity and receive major interest from the industry. Yet, no FDA-approved test for blood-based early cancer detection and MRD testing exists. The novel tests in development, focus on circulating tumor DNA detection. This is limited by low sensitivity, thus lacking clinical validity and utility. The breakthrough CellMate® innovation, fast-tracked to market entry in this FTI project, will fundamentally transform the standard of care for cancer detection. Incorporating the advanced IsoPic™ universal circulating tumor cell capturing, staining technology, and AI-powered bioinformatics workflow, CellMate® detects multiple types of early-stage cancer and MRD with 90% sensitivity. Additionally, the AI-driven decision support functionality enables informed clinical decisions, including personalized treatment suggestions. Based on only a single blood draw, the molecular details of the cancer are provided in 4 days. Technology partners iCellate and QIAGEN (global leader in bioinformatic analysis) team-up with UKSH, a leading oncology institute in Europe. Together we demonstrate CellMate®’s clinical and economic value in a study with breast, ovarian, and pancreatic patients. The extensive network of our consortium ensures a broad outreach to patients, clinicians, healthcare organizations. CellMate® benefits from a multi-billion-euro (>€2.2B) market opportunity that is growing with the cancer screening market rising to ~9B by 2030.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores